Analysis: Richard W. Allen's sell of ABT (Abbott Laboratories)
Assessment: Low signal
A stale 50-day disclosed sale that was part of a broader multi-asset liquidation block, executed on the day of public earnings and directly contradicted by subsequent insider buying.
- Member: Richard W. Allen
- Party / state: Republican (state not provided)
- Chamber: House
- Transaction: Sell
- Amount: $15,001 - $50,000
- Ticker: ABT
- Company: Abbott Laboratories
- Trade date: 2026-04-16
- Disclosure date: 2026-06-05
- Disclosure lag: 50 days
Executive summary
Richard W. Allen (House, Republican) reported selling Abbott Laboratories (ABT) for $15,001-$50,000 on 2026-04-16, disclosed on 2026-06-05 (50-day lag). The sale occurred alongside multiple same-day sales of other equities and Treasury securities. Within the same period, Abbott filed an 8-K on 2026-04-16 reporting Q1 2026 results, and later filings referenced litigation settlement materials and corporate updates.
The member’s ABT activity in the provided trading dataset consists of two purchases in September 2019 and a single sale on 2026-04-16; the dataset does not include matching lot-level purchase data for the 2026 sale return calculation. The ABT sale coincided with a batch of same-day sales across multiple tickers (SPGI, INTU, PG) and sales of U.S. Treasury securities identifiers (91282CJP7, 91282CJR3), plus an additional sale the prior day (AMP), consistent with a multi-asset reduction transaction pattern as recorded. Company event filings available from the user-provided SEC enrichment show Abbott filed an 8-K on 2026-04-16 (Items 2.02, 9.01) announcing Q1 2026 results; subsequent 8-Ks in April included a board-related update (filed 2026-04-27) and an 8-K filed 2026-04-17 referencing derivative litigation and a proposed settlement notice with a hearing date of 2026-06-04. Insider reporting in the provided Form 4 window (through 2026-05-16) includes open-market purchases by a director (10,000 shares on 2026-04-27) and the CFO (2,200 shares on 2026-04-23), along with multiple award/grant transactions (code A) around late March and late April; the dataset also indicates other congressional members traded ABT during 2025-06-16 to 2026-05-27, with several trades within ±30 days of 2026-04-16.
Timeline
- 2019-09-13 — Member purchase of ABT ($15,001-$50,000).
- 2019-09-27 — Member purchase of ABT ($15,001-$50,000).
- 2026-04-15 — Same-day cluster: Sale AMP ($50,001-$100,000).
- 2026-04-16 — Analyzed trade: Sale ABT ($15,001-$50,000). Same-day additional sales: SPGI ($15,001-$50,000), INTU ($15,001-$50,000), PG ($15,001-$50,000), and U.S. Treasury securities identifiers 91282CJP7 ($100,001-$250,000) and 91282CJR3 ($100,001-$250,000).
- 2026-04-16 — Abbott Laboratories filed an 8-K (Items 2.02, 9.01) reporting first quarter 2026 results (date of report/event: 2026-04-16).
- 2026-04-17 — Abbott Laboratories filed an 8-K (Items 8.01, 9.01) referencing pending shareholder derivative litigation and a proposed settlement notice/exhibit (report date 2026-04-10).
- 2026-04-17 — SEC exhibit (EX-99.1) includes notice of proposed settlement in 'In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation' and a settlement hearing scheduled for 2026-06-04 at 9:30 A.M. (U.S. District Court, Northern District of Illinois).
- 2026-04-23 — Form 4: CFO Philip P. Boudreau reported transactions including an open market/private purchase (P) of 2,200 shares at $91.50 and a transaction coded 'I' of 8,909 shares at $92.04.
- 2026-04-24 — Multiple director equity award grants (Form 4, code A) reported around 2026-04-24 (as provided in deterministic EDGAR enrichment).
- 2026-04-27 — Abbott Laboratories filed an 8-K (Items 5.02, 5.03, 5.07, 9.01) reporting board-related updates (event date 2026-04-24; filing date 2026-04-27).
- 2026-04-27 — Form 4: Director Daniel J. Starks reported an open market/private purchase (P) of 10,000 shares at $92.6537.
- 2026-04-28 — Form 4: Executive Vice President Mary K. Moreland reported a transaction coded 'I' for 5,314 shares at $94.41.
Independent analysis of public financial disclosures. Not financial or investment advice.